• Claw Intelligence

  Participated · Seed · Apr 2026

  Claw Intelligence is developing an integrated intelligence layer for Web3 that aims to lower user barriers to the Web3 ecosystem and computing resources. The platform offers encrypted native MCP services and converts fragmented data endpoints into interactive workflows. Key features described include a secure, isolated LLM code-execution sandbox for running code without compromising host security and an LLM-based cross-device multi-computer control that allows centralized management of multiple computers, servers, and devices via natural language through a single web interface. The company completed a $3.0 million seed financing led by investors including Castrum Istanbul, Titans Ventures, Super Labs, and Genesis Capital. The reporting did not disclose revenue, user metrics, a valuation, or specific plans for deploying the new capital.

• AetheriumX

  Participated · Equity · Jan 2026

  AetheriumX operates an interactive on-chain growth system that converts users’ non-custodial assets into participatory, composable yield strategies via its Distributed Capital Intelligence Protocol. The platform integrates DeFi, GameFi, prediction markets, and creator-economy functions, all coordinated by a programmable strategy execution layer. Its dual-token structure assigns AXT to ecosystem participation and strategy execution, while VEXA governs risk management and coordination, aiming to discourage short-term speculation and foster sustainable collaboration. The infrastructure is designed around auditability and transparent governance, ensuring all yield generation and decision-making processes are verifiable on-chain. With the newly secured capital, AetheriumX plans to optimize DCIP, expand core modules, and establish an ecosystem fund to back developers, studios, and community nodes. The company will also pursue aggressive ecosystem expansion in the Asia-Pacific region, particularly Japan and South Korea. 2026 marks the project’s shift from foundational validation to large-scale ecosystem growth, supported by the $8 million strategic financing announced.

• ZenChain

  Led · Equity · Jan 2026

  Founded in 2017 in Zug, ZenChain is building a Layer-1 network that connects Bitcoin-native capital with EVM-compatible chains. Its core innovation is the Cross-Liquidity Consensus Mechanism (CLCM), which supports cross-chain value transfer, decentralized applications, and unified infrastructure participation. The platform seeks to provide EVM programmability without compromising Bitcoin-aligned security principles, giving developers composable access to both ecosystems. Recent testnet traction and ecosystem growth were cited by investors as evidence of the team’s execution speed and precision. The company’s roadmap includes a forthcoming Token Generation Event (TGE) and subsequent mainnet launch. Proceeds from its latest funding will accelerate core protocol development, expand validator participation, and fund go-to-market initiatives. No revenue, usage, or other operating metrics have been publicly disclosed.

• AusperBio

  Participated · Series B · Sep 2025

  AusperBio is a privately held biotech with operations in the United States and China that focuses on advancing oligonucleotide and targeted-delivery technologies. Its proprietary Med-Oligo™ ASO platform is designed to enhance antisense oligonucleotide therapeutics across viral, metabolic, genetic and immune diseases. The lead candidate, AHB-137, is a dual-mechanism, unconjugated ASO that has finished a global Phase I study and is now in multiple Phase II trials as well as a pivotal Phase III trial in China. Clinical data presented at major liver conferences (EASL, AASLD, APASL) have reinforced AHB-137’s potential as a backbone therapy for chronic hepatitis B. With the newly raised capital, AusperBio plans to accelerate pivotal development of AHB-137, launch additional Phase II combination studies, and expand global Phase II efforts. The funds will also support scaling commercial manufacturing partnerships and advance a broader preclinical pipeline. While revenue and user metrics are not disclosed, the company remains financed by a strong syndicate of life-science investors that have demonstrated continued confidence in its platform and development trajectory.

• Reprieve Cardiovascular

  Participated · Series B · Aug 2025

  Reprieve Cardiovascular is a clinical-stage medical device company headquartered in Milford, Massachusetts, developing the Reprieve system to personalize decongestion management for patients with acute decompensated heart failure (ADHF). The Reprieve system combines real-time physiological monitoring with automated recommendations and precise diuretic dosing while replenishing saline to support kidney function, aiming to safely, quickly, and thoroughly remove excess fluid. The company completed a randomized FASTR pilot study that met primary efficacy and safety endpoints and has initiated the larger FASTR II pivotal trial, enrolling its first patient. FASTR II plans to enroll up to 400 patients across the United States and Europe and will support a future premarket approval submission in the United States. Proceeds from the oversubscribed $61 million Series B, which combined equity investment with a debt facility, will support rapid execution of the FASTR II trial and key commercial readiness activities. Reprieve says it seeks to improve outcomes and reduce readmissions for the more than 25 million people globally who suffer from heart failure. Reprieve Cardiovascular is a development-stage, privately held medical device company developing the Reprieve System, an intelligent automated diuretic and fluid-management platform to personalize decongestion for acute decompensated heart failure patients. The system monitors physiological parameters such as urine output to deliver personalized diuretic dosing and fluid replacement, aiming to safely and quickly remove excess fluid, improve outcomes, and reduce readmissions. The company emerged from stealth after announcing a $42 million Series A to advance clinical and development programs. Proceeds will support the ongoing FASTR pilot trial (initiated in 2022) and an upcoming pivotal trial; the FASTR trial is enrolling patients in the United States and Europe. Leadership has grown with domain experts across product development, regulatory, clinical, and commercial strategy. Reprieve is headquartered in Milford, Massachusetts.

No current team members are available.